Mission Statement
Our mission is to characterize the key molecular and phenotypic pathways important in prostate cancer development and progression in order to improve the health of prostate cancer patients through informed treatment and prevention strategies. To accomplish this goal, we seek to identify the key biological markers that can be implemented clinically to refine prostate cancer treatment decisions and to define biomarkers of susceptibility, prediction, and prognosis to impact men's health. We address this goal through an international, multi-discipline consortium of prostate cancer researchers and clinicians with access to unique biobanks of prostate cancer populations from the US and across Europe. We believe the synergy created by combining the population science perspective of epidemiology and biostatistics with molecular pathology, genetics and oncologic clinical expertise will allow us to answer fundamentally important questions about prostate cancer.
Featured Researcher
Lorelei Mucci - Lorelei Mucci is an Associate Professor of Epidemiology at the Harvard School of Public Health. She is one of the two co-leaders of ToPCaP.
Featured
Project
Shedding light on stromal – epithelial interactions in prostate cancer carcinogenesis and mortality -